ストックスクリーナーアプリを入手
6.85
1.93%
0.13
Fennec Pharmaceuticals Inc (FENC) 最新ニュース
FENC (Fennec Pharmaceuticals) posts far wider than expected Q4 2025 loss even as shares tick higher.Expert Verified Trades - Newser
Book value per share of Fennec Pharmaceuticals Inc. – TSX:FRX - TradingView
Insider Selling: Adherex Technologies (NASDAQ:FENC) Director Sells 10,781 Shares of Stock - MarketBeat
Director at Fennec (NASDAQ: FENC) sells shares after tax-related option exercise - Stock Titan
FENC (NASDAQ: FENC) insider files Form 144 to sell 10,781 shares - Stock Titan
Fennec (NASDAQ: FENC) CCO acquires 168 newly released shares - Stock Titan
Fennec Pharmaceuticals (NASDAQ: FENC) CSO gains 155 vested shares - Stock Titan
Fennec (FENC) CEO acquires 1,159 shares as restrictions lift - Stock Titan
Fennec Pharmaceuticals (FENC) CFO gains 1,703 additional shares - Stock Titan
Restricted share vesting adds 168 shares for Fennec (FENC) CMO - Stock Titan
FENC Stock Price, Quote & Chart | FENNEC PHARMACEUTICALS INC (NASDAQ:FENC) - ChartMill
Director to retire as Fennec Pharmaceuticals (FENC) Board shrinks to five seats - Stock Titan
1.98M shares disclosed by Fennec holders (NASDAQ: FENC) in Schedule 13G - Stock Titan
Large equity incentive proposals at Fennec Pharmaceuticals (NASDAQ: FENC) 2026 meeting - Stock Titan
(FENC) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
FENC Fennec Pharmaceuticals Inc. reports wider than expected Q4 2025 loss, as shares rise nearly 8 percent in today’s trading.FCF Yield - Cổng thông tin điện tử Tỉnh Sơn La
Fennec Showcases New PEDMARK Data at 2026 ASCO - TipRanks
Fennec Pharmaceuticals (FENC) to feature four PEDMARK ototoxicity studies at ASCO 2026 - Stock Titan
Fennec Pharmaceuticals advances PEDMARK as four abstracts accepted for ASCO scientific program - Traders Union
Fennec Pharmaceuticals : Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - marketscreener.com
Fennec Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - marketscreener.com
Fennec Pharmaceuticals Announces Acceptance of Abstracts at the 2026 ASCO Annual Meeting - The Manila Times
Four ASCO studies spotlight hearing-loss risk tied to cisplatin - Stock Titan
Fennec Pharmaceuticals (FENC) Stock One Cancels Other (Weakens) 2026-04-20Most Watched Stocks - Xã Vĩnh Công
(FRX) Strategic Equity Report (FRX:CA) - Stock Traders Daily
Fennec Pharmaceuticals (TSE:FRX) Stock Price Passes Below Fifty Day Moving AverageHere's What Happened - MarketBeat
Fennec Pharmaceuticals (FENC) Receives a Buy from Wedbush - The Globe and Mail
Adherex Technologies (NASDAQ:FENC) Given "Outperform" Rating at Wedbush - MarketBeat
(FENC) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Fennec Pharmaceuticals (FENC) Stock Dividend Capture (Ticks Up) 2026-04-15Senior Analyst Forecasts - Cổng thông tin điện tử tỉnh Lào Cai
(FRX) Trading Report (FRX:CA) - Stock Traders Daily
Treasury Yields: Can Fennec Pharmaceuticals Inc stock outperform in a bear market2026 Reactions & Verified Entry Point Detection - baoquankhu1.vn
US Market Recap: What is the long term forecast for Fennec Pharmaceuticals Inc stock2026 Key Lessons & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Stock Recap: Can Fennec Pharmaceuticals Inc expand its profit marginsGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving AverageWhat's Next? - MarketBeat
FRX.CA Forecast, Price Target & Analyst Ratings | FENNEC PHARMACEUTICALS INC (TSX:FRX) - ChartMill
Aug Spikes: Why is Fennec Pharmaceuticals Inc stock going down2026 Macro Impact & Fast Exit Strategy with Risk Control - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI) and Fennec Pharmaceuticals (FENC) - The Globe and Mail
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study - Investing.com India
H.C. Wainwright reiterates Fennec Pharmaceuticals stock rating on expanded study By Investing.com - Investing.com South Africa
Fennec Pharmaceuticals Announces New Investigator-Sponsored Study of PEDMARK® for Preventing Cisplatin-Induced Hearing Loss in AYA and Adult Cancer Patients - Minichart
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
Fennec Pharmaceuticals: University of Arizona launches PEDMARK study in AYA and adult cisplatin patients - TradingView
Fennec (FENC) backs new University of Arizona study on PEDMARK use in cisplatin-treated patients - Stock Titan
Fennec Pharmaceuticals Inc. Announces Investigator-Sponsored Study of PEDMARK in AYA and Adult Patients With Solid Tumors Receiving Cisplatin - marketscreener.com
Fennec Pharmaceuticals urges focus on community and science to shape a healthier world - Traders Union
Fennec Pharmaceuticals: University Of Arizona Cancer Center Investigator-Sponsored Study Advances PEDMARK In AYA And Adult Cancer Patients - Pulse 2.0
FENC Technical Analysis & Stock Price Forecast - Intellectia AI
Fennec Backs New PEDMARK Study Expanding Cisplatin Ototoxicity Research to Adult Cancers - TipRanks
Fennec Pharmaceuticals Announces Investigator-Sponsored Study to Be Conducted by University of Arizona Cancer Center - Bitget
Can a hearing-loss drug help more adults on cisplatin? Arizona study starts - Stock Titan
Trend Recap: Can Fennec Pharmaceuticals Inc sustain earnings growth2026 Short Interest & Step-by-Step Swing Trade Plans - baoquankhu1.vn
(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily
FENC Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Adherex Technologies (NASDAQ:FENC) Cut to Hold at Wall Street Zen - MarketBeat
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):